

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-19-NFRP-CTA</p>	<p>Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (NF). • Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted. • <i>Must support a clinical trial and may not be used for preclinical research studies.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$800,000 in direct costs (\$1,000,000 in direct costs if requesting the Qualified Collaborator Option). • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): May 23, 2019 5:00 p.m. Eastern time (ET)</p> <p>Application: June 6, 2019 11:59 p.m. ET</p>
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-19-NFRP-EHDA</p>	<p>Investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> • Supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in NF research. • <i>Preliminary and/or published data encouraged but not required.</i> • Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): May 23, 2019 5:00 p.m. ET</p> <p>Application: June 6, 2019 11:59 p.m. ET</p>

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-19-NFRP-IIRA</p>	<p>Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period for the entirety of the award.</p>	<ul style="list-style-type: none"> • Supports highly rigorous, high-impact research with the potential to make an important contribution to NF research and/or patient care. • <i>Preliminary and/or published data required.</i> • Optional Features: Applications meeting criteria identified in the announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI). • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$525,000 in direct costs. • The maximum allowable funding for applications including either the Optional Qualified Collaborator <i>or</i> the NF-OSI Option is \$575,000 in direct costs. • The maximum allowable funding for applications including both the Optional Qualified Collaborator Option and the NF-OSI Option is \$625,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p style="text-align: center;">Pre-Application (Letter of Intent): May 23, 2019 5:00 p.m. ET</p> <p style="text-align: center;">Application: June 6, 2019 11:59 p.m. ET</p>

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>New Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-19-NFRP-NIA</p>	<p>Must be either:</p> <ul style="list-style-type: none"> • An independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project; <i>or</i> • An established independent investigator in an area other than NF <i>at or above</i> the level of Assistant Professor seeking to transition into a career in NF research and must plan to commit at least 10% of his/her effort toward the proposed research project. <p>To be eligible, applicants may not have received more than \$300,000 in direct costs for NF research as a Principal Investigator of one or more Federally funded, non-mentored peer reviewed grants.</p>	<ul style="list-style-type: none"> • Supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in NF research. • Prior experience in NF research is not required. • <i>Preliminary and/or published data relevant to NF and the proposed research project is required.</i> • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$450,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): May 23, 2019 5:00 p.m. ET</p> <p>Application: June 6, 2019 11:59 p.m. ET</p>

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-19-NFRP-EIRA</p>	<p>The investigator must:</p> <ul style="list-style-type: none"> • Be involved in a postdoctoral training or medical residency program; and • Possess at least 1 and up to 4 years of continuous postdoctoral research experience by the Early Investigator Research Award application submission deadline; and • Possess a clinical doctoral degree (i.e., Ph.D., M.D./Ph.D., D.O./Ph.D.) or a clinical doctoral degree (i.e., M.D./D.O. or Ph.D. in a clinical discipline) from an accredited organization or program. 	<ul style="list-style-type: none"> • Supports NF-focused research opportunities for individuals in the early stages of their careers. • Investigators must have a designated mentor who is an experienced NF researcher. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$200,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-application (Letter of Intent): May 23, 2019 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation: June 11, 2019 5:00 p.m. Eastern Time</p> <p>Application: June 6, 2019 11:59 p.m. ET</p>